CYP17A1 and pseudohypoaldosteronism: In conclusion, oteseconazole, VT-1598 and quilseconazole exhibit a negligible risk of causing pseudohypoaldosteronism as they neither inhibited the adrenal enzymes CYP11B1 and CYP17A1 needed for cortisol production nor the peripherally expressed 11β-HSD2 that prevents excessive glucocorticoid-dependent MR activation.